Today: 1 July 2026
CoreWeave hit by securities fraud class action as CRWV investors face March 13 deadline
20 January 2026
1 min read

CoreWeave hit by securities fraud class action as CRWV investors face March 13 deadline

NEW YORK, Jan 20, 2026, 08:33 (EST)

  • Lead plaintiff motions must be filed by March 13 in a securities class action related to CoreWeave purchases made between March 28 and Dec. 15, 2025
  • The complaint focuses on claims regarding meeting customer demand and depending on just one data-center supplier
  • Separate investor notices point to the collapsed Core Scientific deal and data-center delays as major developments

CoreWeave is now the target of a securities fraud class action filed in U.S. federal court. Several plaintiff firms are pushing investors to step forward for lead plaintiff status before the March 13 cutoff.

This is crucial since the lead plaintiff—typically the shareholder with the largest losses—gets to pick the lawyers and direct the case, influencing settlement negotiations and strategy from the outset.

The lawsuit hits a sensitive issue for cloud infrastructure firms: whether they can actually activate data-center capacity quickly enough to meet what they’ve sold.

Kessler Topaz Meltzer & Check stated the complaint claims CoreWeave “overstated” its capacity to satisfy customer demand and minimized the risks tied to depending on a single third-party data-center provider, which the lawsuit argues may impact revenue. NewMediaWire

A separate investor notice from the DJS Law Group highlights that the case involves claims under the Securities Exchange Act, specifically Rule 10b-5 — the SEC regulation frequently invoked in lawsuits over alleged material misstatements tied to securities trading.

The Schall Law Firm highlighted CoreWeave’s botched effort to acquire Core Scientific and setbacks in activating data centers, arguing that subsequent media reports revealed operational problems the complaint says weren’t fully disclosed.

The lawsuit, Masaitis v. CoreWeave, Inc. et al, was filed on Jan. 12 in the U.S. District Court for the District of New Jersey. It lists CEO Michael Intrator, CFO Nitin Agrawal, and development head Brannin McBee as defendants, the complaint shows. The filing references a Nov. 11 CNBC interview where Intrator claimed the company was “not losing any customers” and described the issue as “a delay of a quarter.”

Kessler Topaz’s case summary links investor losses to disclosures made in late 2025, highlighting the collapse of the planned Core Scientific deal and a revenue guidance cut tied to a third-party data-center developer falling behind schedule.

CoreWeave’s IPO prospectus lists its competitors as major general-purpose cloud players like Amazon’s AWS, Google Cloud, IBM, Microsoft’s Azure, and Oracle. It also names smaller AI-centric firms, including Crusoe and Lambda.

Yet securities class actions drag on and carry plenty of uncertainty. Judges frequently throw out cases lacking a clear false statement or a direct connection between disclosures and investor losses. So far, the class itself hasn’t been certified.

CoreWeave shares climbed roughly 6% in early trading Tuesday. According to notices from the law firm, investors who purchased during the class period don’t need to pursue lead-plaintiff status to stay involved in the case.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • 5 Stocks With Strong Relative Price Strength to Watch in H2 2026
    July 1, 2026, 9:58 AM EDT. Wall Street kicked off the second half of 2026 with solid economic growth, robust corporate earnings, and easing geopolitical tensions. The Federal Reserve's hawkish stance and talk of possible rate hikes haven't stopped gains in healthcare and consumer staples, which have outpaced the ongoing AI trade. For this market, investors are looking at stocks with strong relative price strength-names outperforming peers over 1, 4, and 12 weeks. Neurocrine Biosciences, MYR Group, Block XYZ, Delek US Holdings, and Dycom Industries made the list, each backed by earnings estimate boosts and a top Zacks Rank 1. The picks are beating the S&P 500, and fresh analyst upgrades could keep momentum going in the second half.
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus
Next Story

Accenture stock price rises as Palantir-backed “sovereign AI” data-center deal grabs focus

Go toTop